Digital Health Bits

Share on twitter
Share on linkedin
Share on facebook
Share on reddit
Share on pinterest

This #AI Identifies Genetic Disorders by Looking at Face Shape

Rare genetic disorders are, by definition, rare. That can make diagnosing them difficult for clinicians, and without a proper diagnosis, a patient might not receive the best possible treatment.

A new AI-powered smartphone app called Face2Gene could change that.

Its creators say it can outperform doctors at diagnosing rare genetic disorders in children by analyzing kids’ faces. Eventually, the app could help children across the globe receive better treatment for their conditions — if it can overcome a few hurdles.

The Face2Gene app is the work of Boston-based digital-health company FDNA, which describes its work in a paper published in the journal Nature Medicine on January 7th.

#AI#ArtificialIntelligence #DigitalHealth

Smart #Wearable Harnesses the Power of Neurostimulation and AI to Attack the Chronic Pain Crisis

NeuroMetrix has unveiled its smartest, smallest and most powerful #wearable #therapeutic to date. With new features seen for the first time at CES, the recently launched Quell® 2.0 is 50% smaller, yet 20% more powerful than its predecessor. The Company will introduce new functions at CES that include updates to the Quell app like coaching that helps users achieve the best possible outcomes. It also takes Pain Tech to a new level with an “Intensive Therapy” option and is the first wearable technology to utilise machine learning to deliver unprecedented personalization for the treatment of chronic pain.

A Class II medical device, Quell® 2.0 is an advanced form of transcutaneous electrical nerve stimulation (TENS). The device is worn on the leg, regardless of the site of pain, and sends neural pulses to the brain that trigger a natural pain relief response in the central nervous system.

Worn in a breathable soft, flexible band, the Quell device has a credit card sized footprint so that it is discreet and comfortable under clothing. Quell 2.0 is powered by a proprietary neurostimulation microchip.

#Philips Cares App Launches to Digitize the Aging and Caregiving Experience

Role reversal, complexity and cost put tremendous strain on families as they go through the challenges of aging. To help family caregivers be there for their loved ones, easing and enriching their aging journey, Philips launched Philips Cares app at CES. Whether caring for a loved one or for themselves, Philips Cares Aging & Caregiving service is a digital experience that enables people to easily form and activate a care circle of trusted family and friends, access meaningful insights into their loved one’s wellbeing and receive notifications about care.

Philips Lifeline personal alert service can also be managed through the digital experience, and just as before, an aging loved one can still with the simple press of their Philips Lifeline personal alert button connect with a trained care specialist 24/7 to dispatch the right kind of help.


Propeller #Health announces My Pharmacy, enabling in-app pharmacy experience for patients with asthma and COPD

Propeller #Health, a leading #digital #therapeutics company, announced on January 9th “My Pharmacy”, connecting Propeller users living with #asthma and chronic obstructive pulmonary disease (#COPD) directly to pharmacy services in the Propeller mobile app.

Walgreens is the first pharmacy to be included in the new My Pharmacy feature, giving Walgreens patients a single platform for managing their asthma or COPD medication regimen.

Through My Pharmacy, patients will be able to refill prescriptions for in-store pickup at Walgreens pharmacies, locate a nearby Walgreens pharmacy, talk live with a pharmacist through Walgreens Pharmacy Chat and check their Walgreens Balance Rewards™ points, all within the Propeller app.

My Pharmacy will be rolled out to users on Propeller for iOS this week and will be available on Propeller for Android in the coming month, with plans to expand to other programs and partners this year.

“Our collaboration with Propeller is the latest example of our focus on working with #healthcare companies to bring new, innovative services to our patients and customers,” said Giovanni Monti, VP and director of healthcare innovation, Walgreens Boots Alliance.

Read more:

#IBM’s new #AI warns diabetes patients of dangerous blood sugar levels

From diagnostic fingernail #sensors to the use of its #Watson platform to help invent new drugs, #IBM has impressively positioned itself at the forefront of medical tech. On January 3rd, it announced the latest project in this field: a new mobile app feature that’s designed to work as an early warning sign for diabetics about the perils of “going low” on their blood sugar levels.

To the uninitiated, keeping these blood sugar levels in check sounds easy: Simply avoid eating food with too much sugar and you’re good to go. However, the reality is that things are more complicated than that. A person living with type 1 diabetes has to make upwards of 180 decisions every single day, all of which can affect their well being. These can range from how long to sleep or exercise to when that person should have a cup of coffee. It’s an enormous amount of data to juggle — and, should consistent wrong decisions be made, the result can be weakness, fainting and, potentially, even death.

Fortunately, where humans struggle to weigh up complex data sets, #machine #learning tools turn out to be pretty darn great at it. This is what IBM and the world’s largest medical device company Medtronic have attempted with their new predictive tool. Baked into the Sugar.IQ app, IQcast analyzes your data to assess the likelihood of you “going low” within the next several hours.

#Cardiovascular Disease Is Preventable, and #Digital Tools Can Help, Authors Find

Two cardiologists writing for a major European journal called for increasing personalized care for #cardiovascular #health (CVH), by identifying those at risk much earlier than we now do and by using mobile phones that people carry around to boost patient accountability for their own care.

David M. Leistner, MD, and Ulf Landmesser, MD, both of the Department of Cardiology at Charité University Medicine in Berlin, Germany, writing for CardioPulse in the European Heart Journal, noted that the shift toward maintenance of cardiovascular health has been called a “public health revolution” and that 75% of early cardiovascular disease (CVD) is preventable.

The authors recommend both a personalized health strategy that takes advantage of what they call “the genomic revolution” and using #digital tools, especially mobile health, to both collect data and make patients aware in real time of environmental conditions that contribute to poor CVH.

Of note, the CardioMEMS heart failure system has been used to reduce heart failure readmissions by combining biosensors and wearables. The authors note that by 2020, 90% of people over age 6 will have a smartphone, which they say will change the field of cardiovascular prevention.

Related Post